VIEWS: 4 PAGES: 4 POSTED ON: 7/16/2012
E-coli Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to e-coli trends and structure of deals entered into by leading companies worldwide.
E-coli Partnering 2007-2012 Published : July 2012 No. of Pages : 100 Price:US$995 The E-coli Partnering 2007-2012 report provides understanding and access to the e-coli partnering deals and agreements entered into by the worlds leading healthcare companies. Top e-coli deals by value Deals listed by company A-Z, industry sector, stage of development, technology type The E-coli Partnering 2007-2012 provides understanding and access to the e-coli partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides an analysis of e-coli partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors e-coli technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not. This data driven report contains over 30 links to online copies of actual e-coli deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.The initial chapters of this report provide an orientation of e-coli partnering trends. Report scope E-coli Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to e-coli trends and structure of deals entered into by leading companies worldwide. This data driven report includes: Trends in e-coli dealmaking in the biopharma industry since 2007 Access to summary headline, upfront, milestone and royalty data The leading e-coli deals by value since 2007 E-coli Partnering 2007-2012 provides the reader with the following key benefits: In-depth understanding of e-coli deal trends since 2007 Access to summary headline, upfront, milestone and royalty data Insight into key deal terms included in contracts, where disclosed Understand the key deal terms companies have agreed in deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies E-coli Partnering 2007-2012 Table Of contents Executive Summary Chapter 1 – Introduction Chapter 2 – Trends in e-coli partnering 2.1. Introduction 2.2. E-coli partnering over the years 2.3. Bigpharma e-coli dealmaking activity 2.4. E-coli partnering by deal type 2.5. E-coli partnering industry sector 2.6. E-coli partnering by stage of development 2.7. E-coli partnering by technology type 2.8. Disclosed financial deal terms for e-coli partnering 2.8.1 E-coli headline values 2.8.2 E-coli upfront payments 2.8.3 E-coli milestone payments 2.8.4 E-coli royalty rates Chapter 3 – Leading e-coli deals 3.1. Introduction 3.2. Top e-coli deals by value 3.3. Top e-coli deals involving bigpharma Chapter 4 – Dealmaking directory 4.1. Introduction 4.2. Company A-Z 4.3. By deal type Asset purchase Bigpharma outlicensing Co-development Collaborative R&D Co-market Contract service Co-promotion CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Manufacturing Marketing Option Promotion Research Settlement Spin out Sub-license Supply Termination 4.4. By industry sector Academic Bigpharma Biotech Drug delivery Medical device Diagnostic Generic pharma Government Non-profit Pharmaceutical Research tools Services Specialty pharma 4.5. By stage of development Discovery Pre-clinical Phase I Phase II Phase III Registration Marketed 4.6. By technology type Analysis Animal models Assays Bioinformatics Biological compounds Biomarkers Biomaterials Cell culture Cell therapy Clinical testing Diagnostic - companion Devices Diagnostics Discovery tools DNA probes Drug delivery Enabling technology Epigenetics Equipment Facilities Gene therapy Genomics Imaging Industrial chemicals In vitro models Monoclonal antibodies Nanotechnology Oligonucleotide Peptides Personalised medicine Processes Proteomics Radio/Chemo-therapy Recombinant DNA Research services Research supplies RNA therapeutics Screening Small molecules Stem cells Vaccines Chapter 5 – Partnering resource center 5.1. Online partnering 5.2. Partnering events 5.3. Further reading on dealmaking Appendices Appendix 1 – Deal type definitions About Wildwood Ventures Current Partnering Current Agreements Recent titles from CurrentPartnering Order Form – Reports List of Figures
Pages to are hidden for
"E Coli Partnering 2007 2012"Please download to view full document